Yttrium-90 — LLMpedia

Contents

Yttrium-90 Yttrium-90 is a radioactive isotope used primarily in medicine and industry. It originates from nuclear reactors and particle accelerators and features in therapeutic radiopharmaceuticals, industrial tracers, and research involving Los Alamos National Laboratory, Oak Ridge National Laboratory, CERN, Lawrence Berkeley National Laboratory, and Brookhaven National Laboratory. Prominent institutions such as Johns Hopkins Hospital, Mayo Clinic, Memorial Sloan Kettering Cancer Center, University of California, San Francisco, and Massachusetts General Hospital maintain programs that utilize this isotope.

Introduction

Yttrium-90 was identified through studies at facilities including University of Chicago and University of Oxford and has historical connections with projects at Manhattan Project-era laboratories and later efforts at Argonne National Laboratory and Lawrence Livermore National Laboratory. Its application expanded after clinical trials at centers like Stanford University and Cleveland Clinic, with regulatory interactions involving U.S. Food and Drug Administration, European Medicines Agency, and World Health Organization advisory frameworks. Commercial suppliers and radiopharmacy units at organizations such as IBA (company), GE Healthcare, and Lantheus Medical Imaging provide radionuclide products and logistics.

The isotope decays by pure beta emission to stable Zirconium-90 with a mean beta energy that results in a limited tissue penetration range relevant to therapeutic applications; this decay profile has been characterized using instrumentation developed at National Institute of Standards and Technology, Rutherford Appleton Laboratory, and Institut Laue–Langevin. Nuclear data compilations from collaborations including International Atomic Energy Agency and Organisation for Economic Co-operation and Development-Nuclear Energy Agency present evaluated decay schemes, half-life measurements, and beta spectra. Material properties such as specific activity, chemical behavior in acidic and chelating environments, and interactions with matrices were explored in research programs at Massachusetts Institute of Technology, California Institute of Technology, and ETH Zurich. Fundamental studies citing techniques from Marie Curie-era radiochemistry to modern mass spectrometry at Max Planck Society facilities inform its atomic mass characterization.

Standard production routes employ neutron activation of Yttrium-89 targets in research reactors operated by entities like Institut Laue–Langevin, High Flux Isotope Reactor, and Belgian Reactor 2. Alternative accelerator-based methods use proton irradiation at cyclotron centers such as TRIUMF, Fermilab, and Paul Scherrer Institute. Radiochemical separation and purification protocols were refined in programs at Atomic Energy of Canada Limited, National Research Council (Canada), and Japan Atomic Energy Agency, often using ion exchange chromatography and solvent extraction methods pioneered at Dounreay and Sellafield laboratories. Production quality standards follow guidance from Pharmacopoeia Commission, International Atomic Energy Agency, and regional regulators including European Directorate for the Quality of Medicines.

Clinical applications include radioembolization for hepatocellular carcinoma and metastatic liver disease, where microspheres labeled with the isotope are administered by interventional teams at Memorial Sloan Kettering Cancer Center, Royal Marsden Hospital, Karolinska University Hospital, and Asan Medical Center. Radioimmunotherapy using monoclonal antibodies conjugated in trials at Dana–Farber Cancer Institute, MD Anderson Cancer Center, University College London Hospitals, and Hopital Saint-Louis targeted hematologic malignancies and solid tumors. Dosimetry frameworks integrating imaging modalities from Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, and GE Healthcare support treatment planning, while randomized controlled trials coordinated through groups like European Organisation for Research and Treatment of Cancer and National Cancer Institute have evaluated efficacy and safety.

Handling protocols are governed by agencies such as U.S. Nuclear Regulatory Commission, International Atomic Energy Agency, European Commission, and national bodies like Health Canada. Radiopharmacies at hospitals including Johns Hopkins Hospital and Royal Free Hospital implement shielding, contamination control, and waste management practices derived from standards by National Council on Radiation Protection and Measurements and International Commission on Radiological Protection. Transport and packaging comply with International Air Transport Association and International Civil Aviation Organization regulations; licensed carriers and logistics providers such as World Courier manage shipments. Occupational exposure limits and patient release criteria reference guidance from Occupational Safety and Health Administration and Environmental Protection Agency frameworks.

Environmental monitoring programs by United States Geological Survey, Environment Agency (England and Wales), Finnish Radiation and Nuclear Safety Authority, and Swedish Radiation Safety Authority assess release pathways, bioaccumulation potential, and dose modeling. Radiological impact assessments employ models developed at Sandia National Laboratories, Pacific Northwest National Laboratory, and Lawrence Livermore National Laboratory to evaluate groundwater transport, sediment binding, and uptake by biota referencing studies conducted by International Atomic Energy Agency. Remediation and decontamination techniques draw on methods tested at sites managed by United States Department of Energy and remediation projects coordinated with European Commission Directorate-General for Energy.

Category:Radioisotopes